179 related articles for article (PubMed ID: 38099993)
1. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial).
Vizzielli G; Giudice MT; Nardelli F; Costantini B; Salutari V; Inzani FS; Zannoni GF; Chiantera V; Di Giorgio A; Pacelli F; Fagotti A; Scambia G
Ann Surg Oncol; 2024 Feb; 31(2):1207-1216. PubMed ID: 38099993
[TBL] [Abstract][Full Text] [Related]
2. PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Bakrin N; Tempfer C; Scambia G; De Simone M; Gabriel B; Grischke EM; Rau B
Pleura Peritoneum; 2018 Sep; 3(3):20180114. PubMed ID: 30911662
[TBL] [Abstract][Full Text] [Related]
3. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.
Tempfer CB; Winnekendonk G; Solass W; Horvat R; Giger-Pabst U; Zieren J; Rezniczek GA; Reymond MA
Gynecol Oncol; 2015 May; 137(2):223-8. PubMed ID: 25701703
[TBL] [Abstract][Full Text] [Related]
4. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.
Tempfer CB; Celik I; Solass W; Buerkle B; Pabst UG; Zieren J; Strumberg D; Reymond MA
Gynecol Oncol; 2014 Feb; 132(2):307-11. PubMed ID: 24275155
[TBL] [Abstract][Full Text] [Related]
5. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.
Somashekhar SP; Ashwin KR; Rauthan A; Rohit KC
Pleura Peritoneum; 2019 Mar; 4(1):20180111. PubMed ID: 31198851
[TBL] [Abstract][Full Text] [Related]
6. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study.
Struller F; Horvath P; Solass W; Weinreich FJ; Strumberg D; Kokkalis MK; Fischer I; Meisner C; Königsrainer A; Reymond MA
Ther Adv Med Oncol; 2019; 11():1758835919846402. PubMed ID: 31205501
[TBL] [Abstract][Full Text] [Related]
7. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
[TBL] [Abstract][Full Text] [Related]
8. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.
Giger-Pabst U; Solass W; Buerkle B; Reymond MA; Tempfer CB
Anticancer Res; 2015 Apr; 35(4):2309-14. PubMed ID: 25862894
[TBL] [Abstract][Full Text] [Related]
9. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
Tempfer CB; Giger-Pabst U; Seebacher V; Petersen M; Dogan A; Rezniczek GA
Gynecol Oncol; 2018 Jul; 150(1):23-30. PubMed ID: 29743140
[TBL] [Abstract][Full Text] [Related]
10. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
[TBL] [Abstract][Full Text] [Related]
11. Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy - PIPAC-OPC2.
Graversen M; Detlefsen S; Asmussen J; Mahdi B; Fristrup C; Pfeiffer P; Mortensen MB
Pleura Peritoneum; 2018 Jun; 3(2):20180108. PubMed ID: 30911656
[TBL] [Abstract][Full Text] [Related]
12. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
[TBL] [Abstract][Full Text] [Related]
13. Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study.
Tempfer CB; Rezniczek GA; Ende P; Solass W; Reymond MA
Anticancer Res; 2015 Dec; 35(12):6723-9. PubMed ID: 26637888
[TBL] [Abstract][Full Text] [Related]
14. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial.
De Simone M; Vaira M; Argenziano M; Berchialla P; Pisacane A; Cinquegrana A; Cavalli R; Borsano A; Robella M
Biomedicines; 2020 Apr; 8(5):. PubMed ID: 32365877
[TBL] [Abstract][Full Text] [Related]
15. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.
Nadiradze G; Giger-Pabst U; Zieren J; Strumberg D; Solass W; Reymond MA
J Gastrointest Surg; 2016 Feb; 20(2):367-73. PubMed ID: 26511950
[TBL] [Abstract][Full Text] [Related]
16. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer.
Tempfer C; Giger-Pabst U; Hilal Z; Dogan A; Rezniczek GA
Arch Gynecol Obstet; 2018 Aug; 298(2):243-257. PubMed ID: 29869089
[TBL] [Abstract][Full Text] [Related]
17. Randomized control trial comparing quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and intravenous chemotherapy.
Somashekhar SP; Ashwin KR; Rauthan CA; Rohit KC
Pleura Peritoneum; 2018 Sep; 3(3):20180110. PubMed ID: 30911661
[TBL] [Abstract][Full Text] [Related]
18. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
[TBL] [Abstract][Full Text] [Related]
19. [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures].
Jansen-Winkeln B; Thieme R; Haase L; Niebisch S; Pommer C; Lyros O; Zimmer J; Lordick F; Remane Y; Frontini R; Gockel I
Chirurg; 2019 Feb; 90(2):137-145. PubMed ID: 29947920
[TBL] [Abstract][Full Text] [Related]
20. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
Larbre V; Alyami M; Mercier F; Vantard N; Bonnefoy I; Opsomer MA; Villeneuve L; Bakrin N; Rioufol C; Glehen O; Kepenekian V
Anticancer Res; 2018 Dec; 38(12):6869-6875. PubMed ID: 30504403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
